Analysts expect that Valeritas Holdings, Inc. (NASDAQ:VLRX) will post sales of $5.11 million for the current quarter, Zacks reports. Four analysts have made estimates for Valeritas Holdings’ earnings, with the highest sales estimate coming in at $5.29 million and the lowest estimate coming in at $5.00 million. Valeritas Holdings posted sales of $4.89 million during the same quarter last year, which suggests a positive year over year growth rate of 4.5%. The firm is scheduled to issue its next quarterly earnings report before the market opens on Friday, August 11th.

On average, analysts expect that Valeritas Holdings will report full-year sales of $5.11 million for the current financial year, with estimates ranging from $20.95 million to $22.43 million. For the next fiscal year, analysts anticipate that the firm will report sales of $28.15 million per share, with estimates ranging from $26.03 million to $30.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Valeritas Holdings.

Valeritas Holdings (NASDAQ:VLRX) last announced its quarterly earnings results on Friday, May 12th. The company reported ($6.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.72) by $4.20. The company had revenue of $4.61 million for the quarter, compared to the consensus estimate of $4.64 million.

VLRX has been the topic of several analyst reports. ValuEngine lowered Valeritas Holdings from a “sell” rating to a “strong sell” rating in a research note on Thursday, May 11th. Cowen and Company initiated coverage on Valeritas Holdings in a research note on Monday, April 17th. They issued an “outperform” rating on the stock. Wedbush initiated coverage on Valeritas Holdings in a research note on Monday, July 10th. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, B. Riley reiterated a “buy” rating and issued a $10.00 target price on shares of Valeritas Holdings in a research note on Tuesday, April 4th.

Valeritas Holdings (VLRX) opened at 5.21 on Wednesday. The company’s market cap is $35.65 million. Valeritas Holdings has a 52 week low of $4.51 and a 52 week high of $50.00. The company has a 50-day moving average of $5.89 and a 200-day moving average of $13.58.

In related news, insider John Edward Timberlake bought 5,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were bought at an average price of $5.14 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the insider now directly owns 23,037 shares of the company’s stock, valued at $118,410.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 11,500 shares of company stock worth $57,615 in the last quarter. 1.20% of the stock is owned by insiders.

A hedge fund recently bought a new stake in Valeritas Holdings stock. HighTower Advisors LLC bought a new stake in shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned about 1.67% of Valeritas Holdings at the end of the most recent quarter. 11.65% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2017/08/12/5-11-million-in-sales-expected-for-valeritas-holdings-inc-vlrx-this-quarter-updated.html.

About Valeritas Holdings

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas Holdings (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeritas Holdings (NASDAQ:VLRX)

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.